BlackRock Fund Advisors has recently announced that it has increased stake in Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) by 0.67%. After grabbing 11.63 million shares, the institutional investor is now in possession of 77622.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 10.85% having worth around $286.08 million. Moreover, SSgA Funds Management, Inc. increased its share by 0.36 million to have a control over 5.86 million shares. And Fidelity Management & Research Co raised its holdings to 1.58 million shares by acquiring 4.3 million shares or 4.01% of the stake.
Arrowhead Pharmaceuticals Inc. (ARWR) concluded trading on 11/30/23 at a closing price of $21.20, with 5.96 million shares of worth about $126.45 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -38.85% during that period and on Thursday the price saw a loss of about -26.85%. Currently the company’s common shares owned by public are about 107.31M shares, out of which, 101.00M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 12 analysts are covering the ARWR stock and their offered price forecasts bring an average price target of $51.64. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $90.00 and could fall to a lowest price of $24.00. The stock’s current price level is 58.95% above of average price target set by the analysts, while a rise to estimated low would result in gain of 11.67% for the stock. However, touching the estimated high of $90.00 would mean a gain of 76.44% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 53 times over the past 12 months. They bought 739,785 shares in 17 of the transactions. In 36 selling transactions, insiders dumped 326,451 shares.
iShares Core S&P Mid Cap ETF, Vanguard Total Stock Market ETF, and Vanguard Small Cap Index Fund are the top 3 mutual funds which are holding stakes in Arrowhead Pharmaceuticals Inc. iShares Core S&P Mid Cap ETF is currently holding 3.31 million shares of worth totaling $81.4 million. The company recently came buying 0.0 shares which brought its stake up to 3.09% of the company’s outstanding shares. Vanguard Total Stock Market ETF bought 6898.0 shares, after which its hold over company’s outstanding shares expand to 3.02%, leaving 3.24 million shares with the mutual fund that have a worth of about $79.59 million. Vanguard Small Cap Index Fund, after buying 2.63 million shares, have now control over 2.45% of the stake in the company. It holds 7272.0 shares of worth $64.65 million.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) started trading at $28.11, below -$0.87 from concluding price of the previous day. Stock saw a price change of -26.80% in past 5 days and over the past one month there was a price change of -13.79%. Year-to-date (YTD), ARWR shares are showing a performance of -47.73% which decreased to -29.31% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $22.87 but also hit the highest price of $42.48 during that period. The average intraday trading volume for Arrowhead Pharmaceuticals Inc. shares is 993.88K. The stock is currently trading -23.16% below its 20-day simple moving average (SMA20), while that difference is down -19.79% for SMA50 and it goes to -30.70% lower than SMA200.
BlackRock Fund Advisors acquired 11.63 million shares of Arrowhead Pharmaceuticals Inc. having value of about $286.08 million. Data submitted at the U.S SEC by BlackRock Fund Advisors revealed that the firm now holds 77622.0 shares in the company valued at close to $1645586.4, or have control over 0.67% stake in the company. Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) currently have 107.31M outstanding shares and institutions hold larger chunk of about 69.67% of that. Holding of mutual funds in the company is about 44.38% while other institutional holders and individual stake holders have control over 6.43% and 25.42% of the stake respectively.
The stock has a current market capitalization of $2.27B and its 3Y-monthly beta is at 0.91. It has posted earnings per share of -$1.92 in the same period. It has Quick Ratio of 3.98 while making debt-to-equity ratio of 1.41. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ARWR, volatility over the week remained 9.31% while standing at 6.11% over the month.
Analysts are in expectations that Arrowhead Pharmaceuticals Inc. (ARWR) stock would likely to be making an EPS of -$0.85 in the current quarter, while forecast for next quarter EPS is -$0.87 and it is -$2.58 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.99 which is -$0.67 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.39 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -51.12% while it is estimated to decrease by -0.66% in next year. EPS is likely to grow at an annualized rate of 7.33% for next 5-years, compared to annual growth of -24.19% made by the stock over the past 5-years.
Analysts at 12 brokerage firms have issued recommendations for the Arrowhead Pharmaceuticals Inc. (ARWR)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.67. Out of those 12 Wall Street analysts, 8 recommended a “Buy” rating, while 4 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on September 19, 2023 offering a Neutral rating for the stock and assigned a target price of $33 to it.
